Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

NCT02706899 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision based on portfolio prioritization

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: vadastuximab talirine
DRUG: Azacitidine
DRUG: Placebo (for 33A)

Sponsor

Seagen Inc.